Mekinist Den Europæiske Union - dansk - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ikke-småcellet lungekræft (nsclc)trametinib i kombination med dabrafenib er indiceret til behandling af voksne patienter med avanceret ikke-småcellet lungekræft med en braf v600 mutation.

Copaxone 20 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

copaxone 20 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte

teva gmbh - glatirameracetat - injektionsvæske, opløsning i fyldt injektionssprøjte - 20 mg/ml

Copaxone 40 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

copaxone 40 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte

teva gmbh - glatirameracetat - injektionsvæske, opløsning i fyldt injektionssprøjte - 40 mg/ml

Copemyl 20 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

copemyl 20 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte

viatris limited - glatirameracetat - injektionsvæske, opløsning i fyldt injektionssprøjte - 20 mg/ml

Copemyl 40 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

copemyl 40 mg/ml injektionsvæske, opløsning i fyldt injektionssprøjte

viatris limited - glatirameracetat - injektionsvæske, opløsning i fyldt injektionssprøjte - 40 mg/ml

Rinvoq Den Europæiske Union - dansk - EMA (European Medicines Agency)

rinvoq

abbvie deutschland gmbh & co. kg - upadacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Tafinlar Den Europæiske Union - dansk - EMA (European Medicines Agency)

tafinlar

novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuverende behandling af melanomadabrafenib i kombination med trametinib er angivet for den adjuverende behandling af voksne patienter med stadium iii melanom med en braf v600 mutation, efter komplet resektion. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

Copaxone 40 mg/ml injektionsvæske, opløsning, fyldt injektionssprøjte Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

copaxone 40 mg/ml injektionsvæske, opløsning, fyldt injektionssprøjte

orifarm a/s - glatirameracetat - injektionsvæske, opløsning, fyldt injektionssprøjte - 40 mg/ml

Oramorph 20 mg/ml orale dråber, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

oramorph 20 mg/ml orale dråber, opløsning

l. molteni & c. dei f.lli alitti societa di esercizio s.p.a. - morphinsulfat - orale dråber, opløsning - 20 mg/ml

Oramorph 2 mg/ml oral opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

oramorph 2 mg/ml oral opløsning

l. molteni & c. dei f.lli alitti societa di esercizio s.p.a. - morphinsulfat - oral opløsning - 2 mg/ml